BCR-ABL inhibitors for treating chronic myeloid leukemia in chronic phase have transformed a previously incurable malignancy into a manageable condition. However, suboptimal medication adherence has been observed with these agents affecting clinical outcomes and healthcare costs. In order to raise awareness of the problem of adherence, and before developing pragmatic strategies to enhance medication adherence, a deep understanding of the best approaches for measuring adherence in chronic myeloid leukemia patients and identifying non-adherence is required. http://www.ncbi.nlm....les/PMC3943306/
Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges
Posted 07 April 2014 - 09:45 AM
This used poor procedures to determine drug adherence. The primary method was checking prescription orders divided by the number of days. This method does not know when people are on required drug breaks, so they would be called non-adhering. I also wonder how they know what the dosage should be since they admit they do not have individual patient specific information. Overall I think most of us understand what we need to do and do it well, if imperfectly.
You would be called a non-adherer by this study, as would many others following their Onc's direction.
Posted 08 April 2014 - 09:17 PM
Adherence is to conformity as deference is to deformity. Or something like that....
1 user(s) are reading this topic
0 members, 1 guests, 0 anonymous users